February 14, 2020 / 7:29 AM / in 15 days

BRIEF-Verona Pharma Says Phase 2B COPD Study Met Primary Endpoint

Feb 14 (Reuters) - Verona Pharma PLC:

* REG-VERONA PHARMA ANNOUNCES PUBLICATION OF KEY PHASE 2B COPD DATA IN RESPIRATORY RESEARCH

* STUDY MET ITS PRIMARY ENDPOINT

* RELEVANT SECONDARY ENDPOINTS WERE MET INCLUDING SIGNIFICANT PROGRESSIVE IMPROVEMENTS IN COPD SYMPTOMS IN STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below